JTCS Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Eric Lim
Tom Routledge
Imran Masood
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, E.
Right arrow Articles by Large, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, E.
Right arrow Articles by Large, S.
Related Collections
Right arrow Coronary disease

J Thorac Cardiovasc Surg 2004;128:432-435
© 2004 The American Association for Thoracic Surgery


Surgery for acquired cardiovascular disease

Clopidogrel did not inhibit platelet function early after coronary bypass surgery: A prospective randomized trial

Eric Lim, MRCSa,*, Jacqueline Cornelissen, MPhila, Tom Routledge, MRCSa, Stephen Kirtland, PhDa, Susan C. Charman, MScb, Sarah Bellm, BSca, Helen Munday, RGNa, Omar Khan, MRCSa, Imran Masood, MRCSa, Stephen Large, FRCSa

a Departments of Cardiothoracic Surgery and Clinical Pharmacology, Papworth Hospital, Cambridge, UK
b Medical Research Council Biostatistics Unit, Cambridge, United Kingdom

Presented at the Annual Meeting of the Society of Cardiothoracic Surgeons of Great Britain and Ireland, Guernsey, United Kingdom, March 7, 2004.

Received for publication January 25, 2004; revisions received February 19, 2004; accepted for publication March 4, 2004.

* Address for reprints: Eric Lim, Department of Cardiothoracic Surgery, Papworth Hospital, Papworth Everard, Cambridge CB3 8RE, United Kingdom
eric.lim{at}cvsnet.org

OBJECTIVE: Although the beneficial effect of aspirin prescription after coronary surgery has been established, the efficacy of clopidogrel has never been compared with that of aspirin in the critical early postoperative period. We therefore conducted a prospective, double-blind, randomized controlled trial to compare the efficacies of these antiplatelet regimens.

METHODS: Patients undergoing elective primary coronary artery bypass surgery were invited to participate. After the operation, patients were randomized to receive 100 mg aspirin, 325 mg aspirin, or 75 mg clopidogrel tablets daily for 5 days. Our primary outcome measure was platelet aggregation on day 5, expressed as percentage of baseline. Assessment of platelet aggregation was undertaken with the technique of Born.

RESULTS: From September 2002 to July 2003, a total of 54 patients were randomized into the study. There were 2 self-withdrawals and 2 protocol violations, leaving 50 patients for analysis, 34 in the aspirin group and 16 in the clopidogrel arm. Compared with baseline, the mean percentage aggregations with collagen on day 5 were 56% for aspirin and 99% for clopidogrel. The mean difference between the two arms was 42% (95% confidence interval 27%-56%) in favor of aspirin. At the same time point, the effective concentration to inhibit 50% aggregation in the samples from patients randomly assigned to receive clopidogrel were not raised for our entire panel of agonists (changes of –0.04 µg/L for collagen, –0.01 µmol/L for epinephrine, and –0.02 µmol/L for adenosine diphosphate).

CONCLUSION: Clopidogrel, unlike aspirin, did not inhibit platelet aggregation in the first 5 postoperative days and therefore should not be used as a sole antiplatelet agent early after coronary surgery.





This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
E. Lim, S. Carballo, J. Cornelissen, Z. A. Ali, R. Grignani, S. Bellm, and S. Large
Dose-Related Efficacy of Aspirin After Coronary Surgery in Patients With PlA2 Polymorphism (NCT00262275)
Ann. Thorac. Surg., January 1, 2007; 83(1): 134 - 138.
[Abstract] [Full Text] [PDF]


Home page
Canadian J. AnesthesiaHome page
A. Vincentelli, B. Jude, and S. Belisle
Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque].
Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
R. Poston and B. Griffith
Reply to Isbir et al.
Eur. J. Cardiothorac. Surg., September 1, 2005; 28(3): 514 - 515.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
I. Hunt, L. J.H. Blows, and S. J. Patel
Why clopidogrel failed to inhibit platelet function early after coronary artery bypass surgery: To load or not to load, and is it a question of resistance?
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1197 - 1197.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Lim
Reply to the Editor
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1197 - 1198.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
S. G. Raja
Reasons for inability of clopidogrel to inhibit platelet aggregation early after coronary artery bypass surgery
J. Thorac. Cardiovasc. Surg., February 1, 2005; 129(2): 475 - 475.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2004 by The American Association for Thoracic Surgery.